BLOGIR-3, tablets 5 mg 10 pcs

Urticaria, Allergies, Dermatitis, Conjunctivitis, Skin itching, Runny nose, Nasal congestion

• Allergic rhinitis (elimination or relief of sneezing, nasal mucus secretion, palate itching, and red eyes)Allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus discharge, nasal itching, palate itching, itchy and red eyes, lacrimation);
• Spotting (reduction or elimination of skin itching, rash).

.

Indications

Allergic rhinitis (elimination or relief of sneezing, nasal congestion, nasal mucus, itchy nose, itchy palate, itching and redness of the eyes, watery eyes);
urticaria (reduction or elimination of skin itching, rash).

Pharmacological effect

Pharmacodynamics

Special instructions

Impact on the ability to drive vehicles and machinery

At the recommended dose, the drug does not affect the ability to drive vehicles or operate machinery.

However, in very rare cases, some patients may experience drowsiness while taking desloratadine, which may affect their ability to drive or operate machinery.

Active ingredient

Desloratadine

Composition

One lozenge contains:

active substance:

Contraindications

Hypersensitivity to the components of the drug; pregnancy and lactation; age up to 12 years; phenylketonuria.

Side Effects

The frequency of adverse reactions is classified according to the recommendations of the World Health Organization: very often – at least 10%; often – at least 1%, but less than 10%; infrequently – not less than 0.1%, but less than 1%; rarely – not less than 0.01%, but less than 0.1%; very rarely – less than 0.01%, including individual messages.

Interaction

Interactions with repeated combined use of desloratadine with ketoconazole, erythromycin, azithromycin, fluoxetine and cimetidine did not reveal clinically significant changes in the concentration of desloratadine in plasma. BLOGIR-3® does not enhance the effects of alcohol on the central nervous system.

Eating does not affect the effectiveness of the drug.

Overdose

During clinical studies, no clinically significant adverse effects were observed when desloratadine was used in doses up to 45 mg (9 times the therapeutic dose).

Treatment: In case of overdose, take standard measures aimed at removing the active substance from the gastrointestinal tract. Symptomatic and supportive therapy is recommended.

Desloratadine is not eliminated by hemodialysis; the effectiveness of peritoneal dialysis has not been established.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

3 years.

Manufacturer

Jenefarm S.A., Greece